Inoviq Ltd (ASX: IIQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Inoviq Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$46.46 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
140.78 million
Earnings per share
-0.061
Dividend per share
N/A
Year To Date Return
-14.84%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Inoviq Ltd (ASX: IIQ)
Latest News
Healthcare Shares
What's going on with the Inoviq (ASX:IIQ) share price today?
Healthcare Shares
Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?
Share Gainers
BARD1 (ASX:BD1) share price ends stellar day up 41%
Healthcare Shares
BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news
Share Market News
BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is falling 7% today
Share Fallers
Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
Capital Raising
BARD1 (ASX:BD1) share price falls 6% on placement update
Share Market News
Here's why the BARD1 (ASX:BD1) share price is frozen today
Healthcare Shares
Why the BARD1 (ASX:BD1) share price is surging 10% higher
Share Fallers
Why the BARD1 (ASX:BD1) share price plummeted 9% today
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is crushing it today
1❯
IIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Inoviq Ltd
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
IIQ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Mar 2026 | $0.33 | $0.00 | 0.00% | 259,798 | $0.33 | $0.34 | $0.33 |
| 23 Mar 2026 | $0.33 | $-0.03 | -8.33% | 109,321 | $0.34 | $0.34 | $0.33 |
| 20 Mar 2026 | $0.36 | $0.01 | 2.82% | 242,257 | $0.36 | $0.36 | $0.35 |
| 19 Mar 2026 | $0.36 | $-0.01 | -2.74% | 181,218 | $0.33 | $0.36 | $0.33 |
| 18 Mar 2026 | $0.37 | $0.03 | 8.96% | 338,608 | $0.33 | $0.37 | $0.33 |
| 17 Mar 2026 | $0.34 | $0.00 | 0.00% | 13,908 | $0.33 | $0.34 | $0.33 |
| 16 Mar 2026 | $0.34 | $0.01 | 3.03% | 40,410 | $0.34 | $0.34 | $0.33 |
| 13 Mar 2026 | $0.33 | $0.01 | 3.08% | 135,527 | $0.32 | $0.34 | $0.32 |
| 12 Mar 2026 | $0.33 | $0.00 | 0.00% | 181,329 | $0.32 | $0.33 | $0.32 |
| 11 Mar 2026 | $0.33 | $-0.01 | -2.99% | 12,985 | $0.33 | $0.33 | $0.33 |
| 10 Mar 2026 | $0.34 | $0.01 | 3.08% | 45,130 | $0.33 | $0.34 | $0.32 |
| 09 Mar 2026 | $0.33 | $-0.01 | -3.03% | 166,065 | $0.33 | $0.33 | $0.32 |
| 06 Mar 2026 | $0.33 | $0.00 | 0.00% | 8,905 | $0.34 | $0.34 | $0.33 |
| 05 Mar 2026 | $0.33 | $-0.01 | -2.94% | 101,358 | $0.34 | $0.34 | $0.33 |
| 04 Mar 2026 | $0.34 | $0.00 | 0.00% | 68,787 | $0.35 | $0.35 | $0.34 |
| 03 Mar 2026 | $0.34 | $0.01 | 3.03% | 254,015 | $0.33 | $0.36 | $0.33 |
| 02 Mar 2026 | $0.33 | $-0.02 | -5.71% | 302,262 | $0.36 | $0.36 | $0.33 |
| 27 Feb 2026 | $0.35 | $-0.04 | -10.39% | 473,412 | $0.39 | $0.39 | $0.35 |
| 26 Feb 2026 | $0.39 | $0.04 | 11.59% | 132,712 | $0.35 | $0.39 | $0.35 |
| 25 Feb 2026 | $0.35 | $-0.01 | -2.82% | 100,001 | $0.36 | $0.36 | $0.34 |
| 24 Feb 2026 | $0.36 | $0.00 | 0.00% | 244,242 | $0.36 | $0.36 | $0.35 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Mar 2026 | Peter Gunzburg | Buy | 60,000 | $19,269 |
On-market trade.
|
| 02 Mar 2026 | Peter Gunzburg | Buy | 50,000 | $16,500 |
On-market trade.
|
| 19 Feb 2026 | Peter Gunzburg | Buy | 100,000 | $33,000 |
On-market trade.
|
| 05 Nov 2025 | Philip (Phil) Powell | Buy | 85,714 | $29,999 |
Participation in share purchase plan.
|
| 05 Nov 2025 | Robert (Max) Johnston | Buy | 85,714 | $29,999 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Philip (Phil) John Powell | Non-Executive Director | Jun 2019 |
Mr Powell has experience in investment banking, specializing in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. He is the Chair of the Company's Risk Committee.
|
| Mr Peter Lynton Gunzburg | Non-Executive Director | Oct 2025 |
Mr Gunzburg brings over 40 years experience as a public company director, stockbroker, and investor. He previously served as Chairman of BARD1 Life Sciences Limited (now INOVIQ Ltd) from 2016 to 2020. Mr Gunzburg is currently Chairman of Metals X Limited (ASX: MLX) and a Non-Executive Director of London Stock Exchange listed First Tin Plc (LSE: 1SN). Mr Gunzburg has also previously been a director of Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and several other public companies.
|
| Mr Geoffrey A. Cumming | Non-Executive Director | Jul 2020 |
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for 20 years. He is a member of the INOVIQ Limited Risk Committee. He has not been a director of any listed companies in the last three years other than those listed above.
|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Jun 2019 |
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. He has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). He is a member of the Company's Risk Committees. He has not been a director of any listed companies in the last three years other than those listed above
|
| Ms Mary Harney | Non-Executive Director | Oct 2024 |
Ms Harney is a Non-Executive Director and Chief Executive has experience of applied science research, in addition to experience in biopharmaceutical regulatory affairs and commercialization. She is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovative industries such as health, biotech and agriculture. She currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. She was also previously a former Chair of Microbio Limited.
|
| Dr Leearne Hinch | Chief Executive Officer | Nov 2016 |
-
|
| Mr Mark Edwards | Chief Financial OfficerCompany Secretary | Nov 2022 |
-
|
| Leearne Hinch | Chief Executive Officer |
-
|
|
| Mark Edwards | Chief Financial OfficerCompany Secretary |
-
|
|
| DR GREGORY RICE | CHIEF SCIENTIFIC OFFICER |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company Australia Limited <Mof A/C> | 6,487,000 | 5.81% |
| Dr Irmgard Irminger-Finger | 3,150,000 | 2.82% |
| Lawn Views Pty Ltd <Angela Williams Family A/C> | 2,676,924 | 2.40% |
| Lesamourai Pty Ltd | 2,530,495 | 2.27% |
| Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 2,389,747 | 2.14% |
| Mr Peter William Rogers + Ms Alida Johanna Clark <R&C Super Fund A/C> | 1,804,436 | 1.62% |
| J P Morgan Nominees Australia Pty Limited | 1,655,031 | 1.48% |
| Supergun Pty Ltd <Bricklanding Super Fund A/C> | 1,271,000 | 1.14% |
| Trovex Pty Ltd | 1,150,000 | 1.03% |
| Mr Neil Donal Delroy <The Ndd Investment A/C> | 1,135,086 | 1.02% |
| Mr Nathan Ryan Wagner | 1,010,562 | 0.91% |
| Mr Adam Garrigan | 1,000,000 | 0.90% |
| Faraday Nominees Pty Limited <Bronte Investment A/C> | 1,000,000 | 0.90% |
| Palmers Plumbing & Hardware Pty Ltd | 962,256 | 0.86% |
| CITICORP Nominees Pty Limited | 940,051 | 0.84% |
| David Neate | 902,257 | 0.81% |
| S3 Consortium Pty Ltd | 750,000 | 0.67% |
| Jondol Pty Ltd <Jondol Estates S/F A/C> | 711,289 | 0.64% |
| Netwealth Investments Limited <Wrap Services A/C> | 670,394 | 0.60% |
| B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> | 660,000 | 0.57% |